Standard BioTools Inc. Accretion (Amortization) of Discounts and Premiums, Investments
Standard BioTools Inc. (LAB) reported Accretion (Amortization) of Discounts and Premiums, Investments of $1.84 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments · last filed 2026-08-05
- Standard BioTools Inc. accretion (amortization) of discounts and premiums, investments for the quarter ending 2026-06-30 was $1.21M, a 65.34% increase year-over-year.
- Standard BioTools Inc. accretion (amortization) of discounts and premiums, investments for the quarter ending 2026-03-31 was $632.00K, a 24.85% decline year-over-year.
- Standard BioTools Inc. accretion (amortization) of discounts and premiums, investments for the quarter ending 2025-12-31 was $462.00K, a 59.19% decline year-over-year.
- Standard BioTools Inc. accretion (amortization) of discounts and premiums, investments for the quarter ending 2025-09-30 was $611.00K, a 65.26% decline year-over-year.
- Standard BioTools Inc. accretion (amortization) of discounts and premiums, investments for fiscal 2025 was $2.64M, a 64.44% decline from fiscal 2024.
- Standard BioTools Inc. accretion (amortization) of discounts and premiums, investments for fiscal 2024 was $7.43M, a 489.61% increase from fiscal 2023.
- Standard BioTools Inc. accretion (amortization) of discounts and premiums, investments for fiscal 2023 was $1.26M, a 87.09% increase from fiscal 2022.
- Standard BioTools Inc. accretion (amortization) of discounts and premiums, investments for fiscal 2022 was $674.00K.
| Period end | Accretion (Amortization) of Discounts and Premiums, Investments 3 month | Accretion (Amortization) of Discounts and Premiums, Investments 6 month | Accretion (Amortization) of Discounts and Premiums, Investments 9 month | Accretion (Amortization) of Discounts and Premiums, Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $1.84M 10-Q · filed 2026-08-05 | $2.30M derived: sum of 3 quarters · filed 2026-08-05 | $2.91M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $632.00K 10-Q · filed 2026-05-06 | $1.09M derived: sum of 2 quarters · filed 2026-05-06 | $1.71M derived: sum of 3 quarters · filed 2026-05-06 | $2.44M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $462.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $1.07M derived: sum of 2 quarters · filed 2026-03-16 | $1.80M derived: sum of 3 quarters · filed 2026-08-05 | $2.64M 10-K · filed 2026-03-16 |
| 2025-09-30 | $611.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $1.34M derived: sum of 2 quarters · filed 2026-08-05 | $2.18M 10-Q · filed 2025-11-04 | $3.31M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $730.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $1.57M 10-Q · filed 2026-08-05 | $2.70M derived: sum of 3 quarters · filed 2026-08-05 | $4.46M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $841.00K 10-Q · filed 2026-05-06 | $1.97M derived: sum of 2 quarters · filed 2026-05-06 | $3.73M derived: sum of 3 quarters · filed 2026-05-06 | $5.62M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $1.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $2.89M derived: sum of 2 quarters · filed 2026-03-16 | $4.78M derived: sum of 3 quarters · filed 2026-03-16 | $7.43M 10-K · filed 2026-03-16 |
| 2024-09-30 | $1.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $3.64M derived: sum of 2 quarters · filed 2025-11-04 | $6.30M 10-Q · filed 2025-11-04 | $7.24M derived: sum of 4 quarters · filed 2026-03-16 |
| 2024-06-30 | $1.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-15 | $4.54M 10-Q · filed 2025-08-15 | $5.48M derived: sum of 3 quarters · filed 2026-03-16 | $5.65M derived: sum of 4 quarters · filed 2026-03-16 |
| 2024-03-31 | $2.66M 10-Q · filed 2025-05-06 | $3.60M derived: sum of 2 quarters · filed 2026-03-16 | $3.77M derived: sum of 3 quarters · filed 2026-03-16 | $3.76M derived: sum of 4 quarters · filed 2026-03-16 |
| 2023-12-31 | $940.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $1.11M derived: sum of 2 quarters · filed 2026-03-16 | $1.10M derived: sum of 3 quarters · filed 2026-03-16 | $1.26M 10-K · filed 2026-03-16 |
| 2023-09-30 | $170.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $156.00K derived: sum of 2 quarters · filed 2024-11-06 | $321.00K 10-Q · filed 2024-11-06 | |
| 2023-06-30 | -$14.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $151.00K 10-Q · filed 2024-08-06 | ||
| 2023-03-31 | $165.00K 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | $674.00K 10-K · filed 2025-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |